Opsonin

2. Sabbir Ahmed
142-11-3962

3.  Opsonin Pharma Ltd. (OPL) develops,
manufactures and markets generic medicines
for human use.

5. Serial Pharma Tk (Crore) Market
Share
Growth %
01 Square 1378 19.18 23.54
02 Incepta 650 9.05 32.17
03 Beximco 620 8.62 40.33
04 Opsonin 355 4.94 26.09
05 Eskayef 348 4.84 24.82

6. Hasan Sikder
142-11-3954

7.  Opsonin Pharma Ltd. operates on 350,000
square feet of manufacturing area.
 4000 stakeholders.
 Opsonin Group employs more than 6000
people.

8.  Quality Assurance procedures ensure that the
quality of products are maintained.packaging
materials and finished product.

9. Sharmin Afroz
142-11-3963

10. • Well diversifies
• Strong R & D
Strength
• Insufficient working
capital.
• Net operating in low
cost market.
Weakness

11. Can add
more
products to
its PF
Modern
Technological
advantages
Opportunity
Fulfilling the
due
commitments
Open market
competition
Threat

12. Farida Hakim
142-11-3980

13.  Political Factors
 Economic Factors

14.  Environmental Factors
 Legal Factors

15. Safia Akther
142-11-3774

16.  Bargain Power Of Customer.
 Bargain Power of Supplier.
 Rivalry Among Existing Firms.
 Threat of Substitute Products.
 Threat of new Entrants.

17. Fahimul Haq
142-11-3968

18. 0%
20%
40%
60%
80%
100%
Very Low
Low
Moderate
High
Very High
Very High High Moderate Low Very Low
Buyer 0 0 2 7 3
Supplier 0 2 2 5 3
Competitor 1 5 3 2 1
Substitute 0 0 3 4 5
New Entrant 6 3 2 1 0
A Small survey
on 12
professional
shows the
following
result

19.  The pharmaceutical industry is highly
complex. The technologies leading to drug
discovery and development are at the limits
of human knowledge.